Xilio's second bailout
AbbVie follows Gilead in throwing Xilio a lifeline.
NextCure joins the B7-H4 brigade
Meanwhile, Olema’s KAT6 inhibitor will take on rival projects from Pfizer and Menarini.
Bristol changes tack in Claudin18.2
A tie-up with LaNova was terminated, perhaps in favour of a molecule originated by I-Mab.
Claudin18.2 expression clouds Elevation's big reveal
Western data on EO-3021 fail to live up to the billing of a Chinese trial.
The month ahead: April’s upcoming events
April will see the first big scientific meeting of the year, and could herald important data from Immutep and GSK.
FDA green and red lights: Q1 2024
A roundup of the first quarter's key oncology drug approvals and rejections.
ASCO Plenary – what Astellas does Keymed might do better
Keymed’s AstraZeneca-partnered anti-Claudin18.2 ADC looks better than Astellas’s zolbetuximab – albeit on an extremely unreliable metric.
